Generate Biomedicines (NASDAQ:GENB) Trading 5.9% Higher – What’s Next?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price shot up 5.9% during trading on Wednesday . The stock traded as high as $12.70 and last traded at $12.68. 466,795 shares were traded during trading, a decline of 14% from the average session volume of 541,836 shares. The stock had previously closed at $11.97.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GENB. Piper Sandler initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 target price for the company. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Guggenheim started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective for the company. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Price Performance

The business has a 50-day moving average price of $13.12.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.